In this context, FZD7 is particularlyrelevant in intestinal cancer,22−25 breast cancer,26−28 and ovarian cancer.29 The considerable interest toward FZD7 due to its role in cancer in combination with a recent increasein structural information for FZDs has put rational drug design ofFZD7 inhibitors at the forefront.5 In silico docking campaigns have resulted in compounds with apparentbiological activity. The gene discussed is FZD7; the disease is cancer.